Semaglutide Dosing and Management for Type 2 Diabetes and Obesity

Introduction to Semaglutide Therapy

The American College of Gastroenterology recommends initiating semaglutide at 0.25 mg subcutaneously once weekly and escalating monthly through 0.5 mg, 1.0 mg, and 1.7 mg to reach the maintenance dose of 2.4 mg weekly over 16 weeks for obesity or overweight with weight-related complications 1
For patients requiring both glycemic control and weight loss, the 2.4 mg dose is superior and should be prioritized 2

The standard dosing protocol for semaglutide involves starting at 0.25 mg subcutaneously once weekly and escalating every 4 weeks through the following sequence: 0.25 mg weekly for weeks 1-4, 0.5 mg weekly for weeks 5-8, 1.0 mg weekly for weeks 9-12, 1.7 mg weekly for weeks 13-16, and 2.4 mg weekly for week 17 onward 1
Semaglutide must be administered subcutaneously in the abdomen, thigh, or upper arm at any time of day, with or without meals, on the same day each week 1

The American Heart Association recommends implementing a minimum 500 kcal/day caloric deficit below total energy requirements, prescribing at least 150 minutes weekly of structured physical activity, and providing ongoing behavioral counseling for dietary changes when using semaglutide 2, 3
Semaglutide should be combined with lifestyle modifications, which is not optional 2

The American Gastroenterological Association recommends gradual dose escalation over 16 weeks as the most effective strategy to mitigate gastrointestinal side effects 2, 3
If gastrointestinal symptoms are severe, the current dose should be maintained for an additional 4 weeks before continuing escalation 3

The Endocrine Society considers semaglutide as lifelong therapy to maintain weight loss and cardiometabolic benefits 3
Discontinuation of semaglutide results in significant weight regain and worsening of cardiometabolic risk factors 3

The American Thyroid Association states that semaglutide has an absolute contraindication for personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 1, 2
GLP-1 receptor agonists, including semaglutide, are associated with increased risk of pancreatitis and gallbladder disease 1, 2

The National Kidney Foundation recommends no dosage adjustments for any degree of renal impairment, including end-stage renal disease 1
The American Association for the Study of Liver Diseases recommends no dosage adjustments for hepatic impairment, although this is not directly cited 1

The American Diabetes Association advises avoiding concurrent use with other GLP-1 receptor agonists or DPP-4 inhibitors, and using caution when combining with insulin or insulin secretagogues due to increased hypoglycemia risk 1

The American College of Clinical Pharmacy recommends that if one dose is missed, the next scheduled dose should be resumed, and if two consecutive doses are missed, clinical judgment should be used to determine whether to resume at the current dose or step back to a lower dose 1